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Introduction {#sec001}
============

Respiratory viruses are among the most common causes of human morbidity and mortality worldwide, especially for infants and young children \[[@pone.0152702.ref001], [@pone.0152702.ref002]\]. The rapid identification is important for both therapeutic and infection control purposes. Diagnoses of viral respiratory tract infection have been performed generally by non-molecular approaches such as direct immunofluorescence and viral culture. They are time-consuming, labor-intensive, and often lack sensitivity or specificity. In the last few years, multiplex RT-PCR assays have been developed to detect respiratory viruses, and many of them have been commercialized, such as xTAG RVP, RVP fast (Luminex Molecular Diagnostics, Toronto, Canada), Resplex II (Qiagen, Mississauga, Canada), FilmArray^®^ Respiratory panel (Idaho Technology Inc., Salt Lake City, UT, USA), Anyplex^™^ II RV16 and Seeplex RV assays (Seegene, seoul, Korea), AdvanSure^™^ real-time RT-PCR (LG Life Science, Seoul, Korea) \[[@pone.0152702.ref003]--[@pone.0152702.ref007]\]. However, many of these assays are costly, or require specialized laboratory equipment \[[@pone.0152702.ref008], [@pone.0152702.ref009]\].

In our previous study, the two--tube multiplex reverse transcription PCR assay (two-tube assay) to detect sixteen respiratory viruses based on the amplicon size differences using automated electrophoresis system is described. The overall detection rate of the two-tube assay for each virus was comparable to those of the Luminex xTAG RVP Fast assay and Seeplex RV15 ACE assay, demonstrating the high sensitivity and specificity of the two-tube assay in the analysis of clinical samples \[[@pone.0152702.ref010]\]. However, two-tube assay has a few drawbacks, such as the size difference of some amplicons are not big enough leading to the difficulty in judging the results by untrained staff, the hands-on two-tube assay is till cumbersome and the internal control is not steadily detected, which limits its wide use in the routine screening in provincial and local Center for Diseases Control and Prevention (CDC) in China. In the present study, we adopted the two-tube assay as a reference, and have been progressively optimized and substantially improved the performance of simultaneous detection of thirteen respiratory viruses types/subtypes, the most frequently detected viral agents of respiratory tract infections documented by Beijing Monitoring Network for Pneumonia between 2012--2014 (unpublished data), in a single-tube assay while maintaining excellent sensitivity and specificity. The targeted 13 respiratory viruses types/subtypes including influenza A virus (FluA), influenza B virus (FluB), seasonal influenza A virus subtypes H1N1 2009 pandemic (09H1N1), seasonal influenza A virus subtypes H3N2 (sH3N2), parainfluenza virus type 1 (PIV1), human rhinovirus (HRV), adenovirus (Adv), parainfluenza virus type 2 (PIV2), parainfluenza virus type 3 (PIV3), parainfluenza virus type 4(PIV4), respiratory syncytial virus A (RSVA), respiratory syncytial virus B (RSVB) and human metapneumovirus (HMPV). The aim of this study is to provide a high throughput screening method for routine surveillance of respiratory virus infection in provincial and local Centers for Disease Control and Prevention, China.

Materials and Methods {#sec002}
=====================

Ethics Statement {#sec003}
----------------

All aspects of this study were performed in accordance with national ethics regulations and approved by the Institutional Review Boards of the Center for Disease Control and Prevention of Hebei. Children's parents were apprised of the study's purpose and of their right to keep information confidential. Written informed consent was obtained from parents or caregivers.

Clinical samples {#sec004}
----------------

Clinical specimens were obtained from 310 hospitalized patients who had acute respiratory infection(ARI) and admitted to the children\'s hospital of Hebei, China bet-ween May-October, 2015. Of those 110 (35.4%) were female and 200 (64.6%) were male. Ages were ranged from 1 months to 11 years old, and 279 (90% were under three years old. Trained staff collected nasopharyngeal aspirates (NPA) by adding 3.5ml of transport medium and stored at −80°C.

Total RNA/DNA was extracted from195μL of clinical sample with addition of 5μL of bacteriophage MS2 as an internal control (10^5^ copies) prior to the extraction using the QIAamp Viral RNA Mini Kit (Qiagen, Hilden, Germany). The extracts were eluted into 50μL of DNase- and RNase-free water and stored at −80°C.

Primers {#sec005}
-------

A total 14 pairs of chimeric primers were added to a single-tube to detect 13 respiratory viruses, and one pair of internal control primer (MS2 F, MS2 R) and one universal primer (Tag) was also added to the tube. The bacteriophage MS2 coat protein derived Virus-like particles (VLPs) was used as an internal control to monitor the extraction and detection process of each specimens \[[@pone.0152702.ref011], [@pone.0152702.ref012]\]. The primers sequences, the target genes, the amplicon sizes, and primer working concentrations are listed in [Table 1](#pone.0152702.t001){ref-type="table"}.

10.1371/journal.pone.0152702.t001

###### Primer information.

![](pone.0152702.t001){#pone.0152702.t001g}

  Primer                                          Sequence 5--3                                                  Gene                 Size(bp)   Concentrations[^a^](#t001fn001){ref-type="table-fn"}
  ----------------------------------------------- -------------------------------------------------------------- -------------------- ---------- ------------------------------------------------------
  **FluA F**                                      `GTACGACTCACTATAGGGAC ATTGGGATCTTGCACTTGATATT`                 **M**                **265**    **100 nM/L**
  **FluA R**                                      `GTACGACTCACTATAGGGATTTTTTTTTGTAGAAACAAGGTAGTTTTTTACTC`                                        
  **FluB F**                                      `GTACGACTCACTATAGGGAGGGACATGAACAACAAAGATGC`                    **NEP/NS1**          **540**    **100 nM/L**
  **FluB R**                                      `GTACGACTCACTATAGGGATGTCAGCTATTATGGAGCTG`                                                      
  **09H1N1F**                                     `GTACGACTCACTATAGGGAGCATTCGCAATGGAAAGAAA`                      **HA**               **244**    **100 nM/L**
  **09H1N1R**                                     `GTACGACTCACTATAGGGATTTTTTTTCCTCAATCCTGTGGCCAG`                                                
  PIV1 F                                          `GTACGACTCACTATAGGGATCTCATTATTACCYGGACCAA`                     HA                   292        87.5 nM/L
  PIV1 R                                          `GTACGACTCACTATAGGGATTTTTTTTCCTGTTGTCGTTGATGTCATA`                                             
  PIV2 F                                          `GTACGACTCACTATAGGGATCTACACTGCATCAGCCAGC`                      HA                   195        50 nM/L
  PIV2R                                           `GTACGACTCACTATAGGGACCCCTAAAAGAGATGAGCCC`                                                      
  PIV3 F                                          `GTACGACTCACTATAGGGATTGTCAATTATGATGGYTCAATCT`                  HA                   231        **50 nM/L**
  PIV3 R                                          `GTACGACTCACTATAGGGAGACACCCAGTTGTGTTGCAG`                                                      
  **PIV4 F**                                      `GTACGACTCACTATAGGGACTGAACGGTTGCATTCAGGT`                      **Phosphoprotein**   **480**    **50 nM/L**
  **PIV4 R**                                      `GTACGACTCACTATAGGGATTGCATCAAGAATGAGTCCT`                                                      
  HRV F                                           `GTACGACTCACTATAGGGACCCCTGAATGYGGCTAACCT`                      5'UTR                145        **100 nM/L**
  HRV R                                           `GTACGACTCACTATAGGGACGGACACCCAAAGTAGTYGGT`                                                     
  HMPV F1[^c^](#t001fn003){ref-type="table-fn"}   `GTACGACTCACTATAGGGACATGCCCACTATAAAAGGTCAG`                    L                    208        100 nM/L
  HMPV R1                                         `GTACGACTCACTATAGGGACACCCCAGTCTTTCTTGAAA`                                                      
  HMPV F2                                         `GTACGACTCACTATAGGGAGAGCTAAYAGAGTGCTAAGTGATG`                  N                    208        50 nM/L
  HMPV R2                                         `GTACGACTCACTATAGGGAACTTTCTGCTTTGCTTCCTGT`                                                     
  Adv F                                           `GTACGACTCACTATAGGGAGCCSCARTGGKCWTACATGCACATC`                 Hexon                339        100 nM/L
  Adv R                                           `GTACGACTCACTATAGGGACAGCACSCCICGRATGTCAAA`                                                     
  RSVA F                                          `GTACGACTCACTATAGGGACATCCCCTCTATGCACAACC`                      F                    159        50 nM/L
  RSVA R                                          `GTACGACTCACTATAGGGACATGTTTCAGCTTGTGGGAA`                                                      
  RSVB F                                          `GTACGACTCACTATAGGGAAAACGAAGATTTCTGGGCTTC`                     F                    280        100 nM/L
  RSVB R                                          `GTACGACTCACTATAGGGATGCGACAGCTCTGTTGATTT`                                                      
  **H3N2 F**                                      `GTACGACTCACTATAGGGACTATTGGACAATAGTAAAACCGGGRGA`               **HA**               **220**    **50 nM/L**
  **H3N2 R**                                      `GTACGACTCACTATAGGGATTTTTTTTTTGTCATTGGGRATGCTTCCATTTGG`                                        
  **MS2 F**                                       `GTACGACTCACTATAGGGAGCATGGTTGTCGTCTCTAGGT`                     **coat protein**     **351**    **50 nM/L**
  **MS2 R**                                       `GTACGACTCACTATAGGGATTTTTTTTTTTTACTTTACGTACGCGCCAGTT`                                          
  **Tag**                                         `GTACGACTCACTATAGGGA` [`b`](#t001fn002){ref-type="table-fn"}                                   **50 nM/L**

^a^ Primer sequences and primer concentrations varied from two-tube assay are marked in boldface.

^b^ The underlined sequences are universal sequences.

^c^ The primers HMPV-1and HMPV-2 are designed to amplify the L gene and N gene, the amplicon sizes of both PCR products are exactly the same.

Two-tube Assay and Detection Method {#sec006}
-----------------------------------

Two-tube assay was performed as described \[[@pone.0152702.ref010]\]. Briefly, one-step RT-PCR Kit (Qiagen, Hilden, Germany) was used for the amplification. A total of 25μL PCR mixture containing 2μL of extracted RNA and varied primer concentrations was subjected to the following conditions: 50°C for 30min, 95°C for 15min, followed by 10 cycles of 95°C for 30s, 55°C for 30s, and 72°C 30 s; 10 cycles of 95°C for 30s, 65°C for 30s, 72°C for 30s; 25 cycles of 95°C for 30s, 48°C for 30s, and 72°C for 30s, and a final incubation at 72°C for 3min, and the products were analyzed on the QIAxcel automatic electrophoresis using QIAxcel DNA High-Resolution kit.

The Single-tube Assay and Detection Method {#sec007}
------------------------------------------

Single-tube assay was performed according to the protocols as described above in two-tube assay with a slight modification of the primer sequences and primer concentration ([Table 1](#pone.0152702.t001){ref-type="table"}).

Analytical methods {#sec008}
------------------

The X^2^-test and Fisher's exact test were performed to analyze the detection agreement between the single-tube assay and the two-tube assay and resolved discordant results.

Results {#sec009}
=======

Performance evaluation using clinical samples {#sec010}
---------------------------------------------

All the comparative detections were double-blind tests performed by trained staff in our laboratory. All of the 310 clinical specimens were simultaneously tested by the single-tube assay and the two-tube assay. The clinical samples are considered as positive when both the targeted pathogen and MS2 are present. The samples are considered to be negative if samples are negative for pathogen but positive for MS2. If both the target and MS2 are absent, the samples are classified as invalid. No invalid sample was found in the optimal single-tube assay. A total of 226 (72.90%, 226/310) and 214 (69.03%, 214/310) samples were detected by the single-tube assay and the two-tube assay, respectively. Viral coinfections were found in 57 specimens (18.38%, 57/310) by the single-tube assay, while in 48 specimens (15.48%, 48/310) by two-tube assay. In our study, PIV3 and HRV were identified to be the viruses most commonly involved in multiple agent infection, while PIV2 and 09H1 were not detected by either of the two methods. All failed results and discordant results were resolved with repeated tests and direct sequencing using the same primers listed in the [Table 1](#pone.0152702.t001){ref-type="table"}.

Comparison of the assay performance {#sec011}
-----------------------------------

As shown in [Table 2](#pone.0152702.t002){ref-type="table"}, there were 23 specimens with discordant results between the two-tube assay and the single-tube assay, all of them were confirmed by sequencing as true positives, A total of 24 additional viruses were detected only by the single-tube assay, including 5Adv, 4HMPV, 3HRV, 2PIV1, 9PIV3 and 1PIV4. The two-tube assay does not include the detection of PIV4. The sensitivity, specificity, negative prediction value (NPV), positive prediction value (PPV), the accordance rate, and the kappa value of each virus for the single-tube assay compared to two-tube assay are shown in [Table 3](#pone.0152702.t003){ref-type="table"}.

10.1371/journal.pone.0152702.t002

###### The confirmed results for specimens with discordant results between the single-tube assay and the two-tube assay.

![](pone.0152702.t002){#pone.0152702.t002g}

  Case no.   Two-tube                                   the single-tube                                  Confirmed results
  ---------- ------------------------------------------ ------------------------------------------------ -------------------
  10         ND[^b^](#t002fn002){ref-type="table-fn"}   **PIV3**[^a^](#t002fn001){ref-type="table-fn"}   PIV3
  23         PIV1                                       PIV1, **HMPV**                                   PIV1, HMPV
  25         ND                                         **HMPV**                                         HMPV
  26         ND                                         **HRV**                                          HRV
  29         ND                                         **Adv**                                          Adv
  68         HRV                                        HRV, **PIV1**                                    HRV, PIV1
  70         ND                                         **HRV**                                          HRV
  79         HRV                                        HRV, **PIV1**                                    HRV, PIV1
  84         HRV,PIV1                                   HRV, PIV1, **Adv**                               HRV, PIV1, Adv
  93         HRV                                        HRV, **PIV3**                                    HRV, PIV3
  99         HMPV                                       HMPV, **PIV3**                                   HMPV, PIV3
  105        ND                                         **Adv**                                          Adv
  108        ND                                         **PIV4**                                         PIV4
  162        PIV3                                       PIV3, **HRV**                                    PIV3, HRV
  246        HRV                                        HRV, **Adv**                                     HRV, Adv
  247        HRV,PIV3                                   HRV, PIV3, **HMPV**                              HRV, PIV3, HMPV
  252        HRV                                        HRV, **HMPV**                                    HRV, HMPV
  255        ND                                         **HRV, HMPV**                                    HRV, HMPV
  279        ND                                         **PIV3**                                         PIV3
  293        ND                                         **PIV3**                                         PIV3
  321        ND                                         **PIV3**                                         PIV3
  378        ND                                         **PIV3**                                         PIV3
  391        HRV                                        HRV, **PIV3**                                    HRV, PIV3

^a^ Discordant results are highlighted in boldface.

^b^ ND stands for not detected.

10.1371/journal.pone.0152702.t003

###### Performance of the single-tube assay for individual target compared with the two-tube assay.

![](pone.0152702.t003){#pone.0152702.t003g}

            No. of specimens: the single tube assay/ two-tube   Performance of the single tube assay compared with the two-tube assay                                                 
  --------- --------------------------------------------------- ----------------------------------------------------------------------- --- ----- ----- ------- ------- ----- ------- ------
  FluA      6                                                   0                                                                       0   304   100   100     100     100   100     1.00
  FLuB      2                                                   0                                                                       0   308   100   100     100     100   100     1.00
  s09H1N1   0                                                   0                                                                       0   310   NA    100     NA      100   100     NA
  PIV1      7                                                   2                                                                       0   301   100   99.34   77.78   100   99.35   0.87
  PIV2      0                                                   0                                                                       0   310   NA    100     NA      100   100     NA
  PIV3      76                                                  9                                                                       0   225   100   96.15   89.41   100   97.1    0.92
  PIV4      0                                                   1                                                                       0   309   NA    99.68   0       100   99.68   0
  HRV       113                                                 3                                                                       0   194   100   98.48   97.41   100   99.03   0.98
  HMPV      31                                                  4                                                                       0   275   100   98.57   88.57   100   98.71   0.93
  Adv       11                                                  5                                                                       0   294   100   98.33   68.75   100   98.39   0.81
  RSVA      9                                                   0                                                                       0   301   100   100     100     100   100     1.00
  RSVB      9                                                   0                                                                       0   301   100   100     100     100   100     1.00
  H3N2      0                                                   6                                                                       0   304   NA    98.06   0       100   98.06   0

Abbreviation: NA, not applicable.

This table shows the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and the kappa values for each target using the confirmed results as the reference for comparison. All the accordance rate values were above 97.10%, except for NA, all the kappa values were above 0.75.

Discussion {#sec012}
==========

Early detection of respiratory virus infections allows clinicians to initiate immediate therapeutic interventions that can reduce complications, antibiotic use, and unnecessary laboratory testing. In this study, we compared the performance of a single-tube multiplex reverse transcription PCR assay with the reference method, a two-tube assay, which has been confirmed to be comparable to the commercial Luminex x TAG RVP Fast assay and Seeplex RV15 ACE detection kit in our previous study. The single-tube assay is also based on the QIAxcel capillary electrophoresis system, which is accessible in most of provincial Centers for Disease Control and Prevention in China. Of the 310 specimens from hospitalized children, a high prevalence of infection and co-infection with the common respiratory viral pathogens were revealed. HRV was found to be most frequently, followed by PIV3. The major discrepancies between the reference two-tube assay and the proposed single-tube assay were the detection rates of HRV, Adv, HMPV, PIV4, PIV1 and PIV3. The 24 viruses detected only by the single-tube assay (5Adv, 4HMPV, 3HRV, and 2PIV1, 9PIV3, 1PIV4) were confirmed by sequencing as true positives. Therefore, the single-tube assay is more sensitive than the two-tube assay for the detection of HRV, HMPV, Adv, PIV, PIV3 and PIV4. The overall detection rate of the single-tube assay for each virus was comparable to that of the two-tube assay (kappa\>0.75) demonstrating the high sensitivity and specificity of the single-tube assay in the analysis of clinical samples.

Compared with the two-tube assay, the single-tube assay revealed better sensitivity, more accurate quality control, less nonspecific amplification, more cost-effective and shorter turn-around time. This improvement might be attributed to several aspects as follows. First, we have replaced human genome RNase P gene in the two-tube assay with bacteriophage MS2 as an internal control. The utility of MS2-based armored RNA as an assay internal control has been documented in many clinical applications \[[@pone.0152702.ref013], [@pone.0152702.ref014]\]. In this study, the internal control MS2 was added to each specimen prior to extraction as an exogenous control to monitor the whole process from nucleic acid extraction to RT-PCR. Second, we inserted a few T nucleotides when appropriate between the specific and universal sequences in the primer design to ensure each amplicon can be easily distinguished by the QIAxcel machine. Third, homologous tail sequences was added to the 5\' end of each chimeric primer \[[@pone.0152702.ref015]\]. The homo-tag assisted non-dimer (HAND) system introduced in this study was to prevent dimer formation and allow more, specific, sensitive, and stable detection of the viruses \[[@pone.0152702.ref016]\]. Fourth, for detection of multiple viral targets, simultaneous presence of multiple targets in one specimen may have led to competitive inhibition of amplification of less abundant targets and may explain some loss of assay sensitivity. In this study, we avoided this problem by optimizing temperature switch PCR parameters and further fine-tuning the concentration of primers. In addition, single-tube assay is more convenient and rapidly to apply to clinical specimens, saving the cost and turn-around time.

In our study, the most frequently detected pathogen was HRV, while in other study, the RSV was the most commonly detected viral pathogen \[[@pone.0152702.ref017], [@pone.0152702.ref018]\]. This difference might be caused by the following two aspects. First, the detection of RSV increased during the winter, whereas HRV was detected year-round \[[@pone.0152702.ref019], [@pone.0152702.ref020]\]. In this study, the samples collection time is not in winter (May to October). Second, HRV is a well-recognized cause of common colds and associated with upper respiratory tract complications. In this study, the patients were hospitalized for both the upper respiratory tract and lower respiratory tract infections.

The two-tube assay does not include PIV4 while single-tube assay does. For PIV4 and PIV2, only one PIV4 specimen was detected as positive and no PIV2 were detected by the single-tube assay with acute respiratory illnesses, which is consistent with previous reports that PIV2 and PIV4 were not identified as frequently as PIV1 and PIV 3 \[[@pone.0152702.ref021]--[@pone.0152702.ref023]\]. The different geographic location might also lead to the different seasonal distributions of PIVs. All of the FluA positives detected by the single-tube assay were subsequently sequenced to be H3N2 infection. 09H1N1 were not detected by either of two methods because H3N2 is the predominant seasonal FluA circulating in 2015 in China. Though PIV2 and 09H1N1 were not found in the samples, we detected a few stock clinical samples previously identified as 09 H1N1 or PIV2 using both single-tube and two-tube assays, and the results demonstrated both assays worked very well (data not shown). Moreover, no false positives were found by the single-tube assay, further suggesting the high specificity of the single-tube assay.

However, the limitations of our study are that only the main causes of respiratory infection were investigated. Other respiratory tract infection related viruses, such as coronaviruses 229E, HKU1, NL63, and OC43, human bocavirus (HBoV), enteroviruses (EV) \[[@pone.0152702.ref017], [@pone.0152702.ref024], [@pone.0152702.ref025]\], are not included in this study. Besides, the association of clinical outcome with the etiology information, particularly the role of co-infections in the clinical course and severity is not addressed. Given the high prevalence (18.38%, 57/310) and diversity of viral co-infections in our study, further research is also needed.

In summary, the improved single-tube assay in this study using automatic capillary electrophoresis is a rapid, cost-effective and reliable method with high sensitivity and specificity for the simultaneous detection of thirteen respiratory virus infections, and will be a valuable tool for routine surveillance of respiratory virus infection in China.
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